Table 2.
Statistical analysis a of treatment differences in change from post-saline baseline (intent-to-treat population)
| Treatment difference | 95% CI | |
|---|---|---|
|
wmFEV
1
(L) | ||
|
FF – placebo |
0.162 |
0.087, 0.237 |
|
FF/VI – placebo |
0.145 |
0.069, 0.222 |
|
FF/VI – FF |
−0.017 |
−0.091, 0.057 |
|
Max. percent decrease (%) | ||
|
FF – placebo |
10.951 |
8.053, 13.848 |
|
FF/VI – placebo |
11.785 |
8.849, 14.721 |
|
FF/VI – FF |
0.834 |
−2.010, 3.678 |
|
Max. absolute decrease in FEV
1
(L) | ||
|
FF – placebo |
0.330 |
0.232, 0.429 |
|
FF/VI – placebo |
0.331 |
0.231, 0.431 |
| FF/VI – FF | 0.001 | −0.096, 0.097 |
aPopulation sizes analysed: placebo, n = 45; FF, n = 49; FF/VI, n = 46. Efficacy endpoints were analysed using a mixed-effects analysis of covariance (ANCOVA) model, with fixed effects of treatment, period, subject-level baseline, period-level baseline, country, sex and age and subject fitted as a random effect.
CI = confidence interval; FEV1 = forced expiratory volume in 1 s; FF = fluticasone furoate; L = litres; VI = vilanterol; wm = weighted mean.